Joint Formulary & PAD

Rituximab - Refractory vasculitis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Not Specified
Associated Icons :
BNF SPC
NHSE
Restrictions / Comments :

Documentation

NICE Technology Appraisal

PAD Profile

ChemicalSubstance :
Rituximab
Indication :
Refractory vasculitis
Group Name :
Keywords :
Vasculitis
Brand Names Include :
MabThera
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Other Drugs

Below are listed other drugs that are used to treat Refractory vasculitis.

  • No records returned.

Committee Recommendations (2)

Commissioned by NHS England. Treatment should be initiated by the specialist and is considered to be a RED drug on the traffic light system. GPs should not be requested to prescribe this treatment
01 Apr 13 - Not Set
Funded by NHS England from 1st April 2013. Treatment should remain with the specialist (RED) hospital only drug.